GlassScriptPhysician profile
Andrew Jon Benn
NPI 1851329270
$121,838.33
in general payments reported to CMS, 2019-2025
36 companies · $1,546 in 2025
The $1,546 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $67K · 2020: $21K · 2021: $24K · 2022: $3,800 · 2023: $1,904 · 2024: $2,007 · 2025: $1,546.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,437 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,436.57 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $98,410.75 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $11,970.36 | 2019-2025 | Camzyos, Eliquis |
| Boston Scientific Corporation | $6,443.24 | 2019-2025 | Lux-Dx Insertable Cardiac Monitor, Watchman Flx, Bodyguardian |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $581.16 | 2023-2025 | Lifevest |
| Novartis Pharmaceuticals Corporation | $476.76 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $452.02 | 2021-2025 | Wainua, Farxiga |
| Amgen INC. | $321.63 | 2021-2025 | Repatha, Repatha |
| Merck Sharp & Dohme LLC | $274.64 | 2021-2025 | Verquvo, Winrevair |
| Esperion Therapeutics, INC. | $228.94 | 2023-2025 | Nexletol |
| Bayer Healthcare Pharmaceuticals INC. | $228.42 | 2023-2025 | |
| Heartflow, INC. | $226.21 | 2020-2025 | Ffrct |
| Boehringer Ingelheim Pharmaceuticals, INC. | $225.71 | 2023-2025 | Jardiance |
| Novo Nordisk INC | $187.52 | 2023-2025 | Ozempic, Rybelsus |
| Lexicon Pharmaceuticals, INC. | $169.84 | 2023-2024 | Inpefa |
| Biotronik INC. | $168.96 | 2021-2023 | Edora 8 Dr-T |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $139.51 | 2023-2024 | Xarelto |
| Alnylam Pharmaceuticals INC. | $123.19 | 2023-2025 | Amvuttra |
| Irhythm Technologies, INC. | $121.71 | 2024 | Zio Monitor, Zio Xt Patch |
| Atricure, INC. | $117.41 | 2023-2025 | Atriclip Laa Exclusion System, Epi-Sense Guided Coagulation System With Visitrax |
| Kiniksa Pharmaceuticals International, Plc | $117.14 | 2024 | Arcalyst |
| Impulse Dynamics (USA) INC. | $112.24 | 2023 | Optimizer |
| Actelion Pharmaceuticals US, INC. | $110.46 | 2023-2025 | Uptravi, Opsumit |
| Baxter Healthcare | $104.46 | 2025 | Hillrom - Carnation Ambulatory Monitor, Hillrom - Cardiac Ambulatory Monitor |
| Abbott Laboratories | $97.70 | 2023-2024 | Gallant, Assurity |
| Kiniksa Pharmaceuticals, LTD. | $84.38 | 2023 | Arcalyst |
| Edwards Lifesciences Corporation | $82.90 | 2024-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Scpharmaceuticals INC. | $55.56 | 2024-2025 | |
| Portola Pharmaceuticals, LLC | $32.72 | 2019 | |
| Abiomed | $31.16 | 2024 | Impella |
| Sanofi-Aventis U.S. LLC | $29.59 | 2024 | |
| Cleerly, INC. | $25.10 | 2025 | Cleerly Labs, Cleerly Ischemia |
| Regeneron Healthcare Solutions, INC. | $20.59 | 2024 | Evkeeza |
| Vifor Pharma, INC. | $19.61 | 2019 | |
| Biogen, INC. | $16.43 | 2024 | Skyclarys |
| Glaxosmithkline, LLC. | $16.10 | 2025 | Shingrix |
| Kestra Medical Technology Services, INC. | $14.21 | 2024 | Assure Wcd |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Benn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.